IPO Overview
Incorporated in 2002, Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. With over 30 years of industry experience, the company has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the US FDA, EU-GMP, Ministry of Food and Drug Safety (Korea), and other global regulatory bodies.
The company operates as a vertically integrated pharma and biotech player with a “microbe-to-pharmacy” and “farm-to-pharmacy” approach — controlling the entire value chain from raw material sourcing and fermentation to finished dosage forms. It supplies products to over 200 customers across 40+ countries, including regulated markets such as the US and Europe, and holds dominant global market share in key corticosteroid and steroidal-hormone APIs.
The company is now bringing its mainboard IPO to raise ₹1,757 crore at the upper end of the price band of ₹938–₹988 per share. The IPO will list on both BSE and NSE, with listing scheduled for September 1, 2026. The issue opens on August 24, 2026 and closes on August 27, 2026.
IPO Detailed Information
Issue Details
| Parameter | Details |
| IPO Type | Book Built – Mainboard |
| Listing Exchange | BSE & NSE |
| IPO Open Date | 24 August 2026 |
| IPO Close Date | 27 August 2026 |
| Allotment Date | TBA |
| Listing Date | 01 September 2026 (Tentative) |
| Price Band | ₹938 – ₹988 per share |
| Face Value | ₹2 per share |
| Lot Size | 15 shares |
| Minimum Investment (Retail) | ₹14,820 (1 lot = 15 shares) |
| Maximum Investment (Retail) | ₹1,92,660 (13 lots = 195 shares) |
| Issue Size | ₹1,757 crore |
| Fresh Issue | ₹150 crore |
| Offer For Sale (OFS) | ₹1,607 crore (approx) |
Note: The issue comprises a fresh issue of ₹150 crore and a large offer for sale by promoters and existing institutional investors worth the remaining amount.
Issue Break-up
| Category | Allocation |
| Qualified Institutional Buyers (QIB) | ~50% |
| Non-Institutional Investors (NII/HNI) | ~15% |
| Retail Individual Investors (RII) | ~35% |
OFS / Selling Shareholders
Prominent selling shareholders include Satwani Holdings LLP and institutional investors such as Rosewood Investments and India Business Excellence Fund-III, who plan to offload shares as part of the OFS.
According to the RHP, promoters including Anil Satwani, Kashish Satwani, Sushil Satwani, Prakash Sawlani, Satwani Holdings LLP, and Goldfin Capital LLP were allotted shares at ₹276 apiece in December 2025 — and at the upper IPO price band of ₹988, these promoters stand to gain approximately 260% in just eight months.
Objects of the Issue (Fund Utilization)
Since the majority of the IPO is an OFS, only the fresh issue proceeds of ₹150 crore will flow to the company. The company proposes to use the net proceeds for prepayment/repayment in full or in part of certain outstanding borrowings, and for general corporate purposes.
- Repayment / prepayment of outstanding borrowings — primary use
- General corporate purposes — remaining proceeds
Lead Managers & Registrar
- Book Running Lead Managers: JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., and Nomura Financial Advisory & Securities (India) Pvt. Ltd.
- Registrar to the Issue: MUFG Intime India Pvt. Ltd.
Promoters & Management
The promoters of the company are Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP. The promoter group collectively holds approximately 27% of the company pre-IPO, with institutional investors such as Rosewood Investments and Motilal Oswal Private Equity holding significant stakes.
Registered Office: 385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh — 453331
Company Details
Symbiotec is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three core platforms. It is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in fiscal 2025.
Sectors Served:
- Pharmaceutical (Corticosteroids & Hormone APIs)
- Nutraceuticals & Nutritional Ingredients
- Specialty & Wellness Products
- CDMO (Contract Development & Manufacturing)
Key Products:
The company holds leadership positions in key corticosteroid and steroidal hormone APIs with global volume market shares exceeding 50% in molecules such as Hydrocortisone (78.9%), Testosterone (70.4%), and Methylprednisolone (50.6%). Its portfolio spans over 60 APIs including Progesterone and Betamethasone.
Manufacturing Facilities:
Symbiotec operates an extensive, multi-scale, vertically integrated manufacturing network across Madhya Pradesh — Rau Facility (Indore) with 92 MT synthesis capacity (USFDA, EU-GMP, WHO-GMP approved); Pithampur Facility (SEZ) with 492.67 MT chemical synthesis and 300 KL fermentation capacity; Ujjain Facility with 400 KL fermentation capacity with biologic expansion underway; and Mhow Facility newly commissioned for complex injectables with 20 million vials annual capacity.
Key Capabilities:
- Chemical synthesis capacity of ~585 MT, fermentation capacity of 700 KL, and injectables capacity of 20 million vials annually.
- Biotransformation, precision fermentation, double chamber platforms, and continuous flow chemistry
Certifications / Regulatory Approvals:
- US FDA
- EU-GMP
- Ministry of Food and Drug Safety, Korea
- WHO-GMP
- CARE A+ Credit Rating
Financial Snapshot
| Period | Total Income (₹ Cr) | PAT (₹ Cr) |
| FY23 | ₹572.97 | ₹23.49 |
| FY24 | ₹723.33 | ₹100.06 |
| FY25 | ₹755.98 | ₹96.79 |
| FY26 | ₹872.26 | ₹109.90 |
Key Financial Metrics
- Revenue grew from ₹723.33 crore in FY24 to ₹755.98 crore in FY25 to ₹872.26 crore in FY26, reflecting consistent top-line expansion.
- PAT moved from ₹100.06 crore in FY24 to ₹96.79 crore in FY25, then recovered to ₹109.90 crore in FY26 — a non-linear path worth noting.
- Revenue grew at a CAGR of 15.18% from FY23 to FY25. The company maintains a CARE A+ credit rating.
- Total borrowings rose significantly from ₹247.21 crore in FY24 to ₹540.92 crore in FY25, before reducing to ₹387.91 crore in FY26.
Company Strengths
- Global leadership position in corticosteroid and steroidal-hormone APIs — the only Indian and global company with presence across the top 10 such APIs in FY25.
- Dominant market shares in critical molecules — Hydrocortisone (78.9%), Testosterone (70.4%), and Methylprednisolone (50.6%) — providing strong pricing power and competitive moats.
- Vertically integrated “microbe-to-pharmacy” model enabling full value chain control — from fermentation to finished dosage forms
- Multi-facility manufacturing network across Madhya Pradesh with international regulatory approvals including US FDA and EU-GMP, enabling access to high-value regulated markets.
- Strong and diversified global customer base of 200+ clients across 40+ countries
- CARE A+ credit rating reflecting strong financial health and debt repayment capacity.
Key Risks & Challenges
- Large OFS component: The fresh issue is only ₹150 crore out of a total ₹1,757 crore — meaning the vast majority of proceeds go to promoters and investors exiting, not to the company for business growth.
- Total borrowings surged from ₹247 crore in FY24 to ₹541 crore in FY25 — a steep rise that signals capital intensity and execution risk, with only a partial reduction to ₹388 crore in FY26.
- PAT volatility: PAT actually declined 3.3% from FY24 to FY25 despite revenue growth — indicating margin pressure in that year.
- Heavy dependence on maintaining US FDA, EU-GMP, and other international regulatory certifications — any lapse could materially impact operations and export revenues.
- Promoters stand to gain ~260% in just eight months on shares allotted at ₹276 in December 2025 — raising concerns about valuation and timing of the public issue relative to promoter entry.
- Business concentrated in the API and specialty pharmaceutical segment — exposed to sector-specific regulatory, pricing, and raw material risks.
Disclaimer:
This document is for informational purposes only and should not be considered as investment advice. Investors should read the Red Herring Prospectus (RHP) carefully and consult a financial advisor before investing in any IPO. Market investments are subject to risk.
